Skip to main content
. 2022 Feb 21;20(6):938–948. doi: 10.1158/1541-7786.MCR-21-0029

Figure 4.

Figure 4. TMZ exposure induces selective vulnerability to BCL-XL inhibitors. GBM76 and GBM39 were treated with TMZ (100 µmol/L) for 7days followed by 14 days of TMZ-free media prior to treatment with BCL-2 family inhibitors as shown. TMZ-treated cells demonstrated selective vulnerability to BCL-XL inhibitors (A1331852, A1155463, navitoclax), but not to the BCL-2–specific inhibitor (venetoclax). For all experiments, luminescence values are normalized individually to 0 nmol/L control. All data are means ± SD of three technical replicates at each concentration.

TMZ exposure induces selective vulnerability to BCL-XL inhibitors. GBM76 and GBM39 were treated with TMZ (100 µmol/L) for 7days followed by 14 days of TMZ-free media prior to treatment with BCL-2 family inhibitors as shown. TMZ-treated cells demonstrated selective vulnerability to BCL-XL inhibitors (A1331852, A1155463, navitoclax), but not to the BCL-2–specific inhibitor (venetoclax). For all experiments, luminescence values are normalized individually to 0 nmol/L control. All data are means ± SD of three technical replicates at each concentration.